RS58744B1 - Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje - Google Patents

Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje

Info

Publication number
RS58744B1
RS58744B1 RS20190433A RSP20190433A RS58744B1 RS 58744 B1 RS58744 B1 RS 58744B1 RS 20190433 A RS20190433 A RS 20190433A RS P20190433 A RSP20190433 A RS P20190433A RS 58744 B1 RS58744 B1 RS 58744B1
Authority
RS
Serbia
Prior art keywords
bendamustine
liquid composition
use according
volume
composition
Prior art date
Application number
RS20190433A
Other languages
English (en)
Serbian (sr)
Inventor
Srikanth Sundaram
Scott L Tarriff
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58744(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of RS58744B1 publication Critical patent/RS58744B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
RS20190433A 2012-03-20 2013-03-15 Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje RS58744B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261613173P 2012-03-20 2012-03-20
US201261669889P 2012-07-10 2012-07-10
US201261678715P 2012-08-02 2012-08-02
PCT/US2013/032295 WO2013142359A1 (en) 2012-03-20 2013-03-15 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
EP13765020.6A EP2827863B1 (en) 2012-03-20 2013-03-15 Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Publications (1)

Publication Number Publication Date
RS58744B1 true RS58744B1 (sr) 2019-06-28

Family

ID=49212373

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20190433A RS58744B1 (sr) 2012-03-20 2013-03-15 Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje
RS20230252A RS64137B1 (sr) 2012-03-20 2013-03-15 Tečne kompozicije bendamustina za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za primenu

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20230252A RS64137B1 (sr) 2012-03-20 2013-03-15 Tečne kompozicije bendamustina za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za primenu

Country Status (17)

Country Link
US (3) US9000021B2 (enExample)
EP (3) EP3533447B1 (enExample)
JP (6) JP6224064B2 (enExample)
CN (2) CN104271135B (enExample)
CA (1) CA2867343C (enExample)
DK (2) DK2827863T3 (enExample)
ES (2) ES2943668T3 (enExample)
FI (1) FI3533447T3 (enExample)
HK (1) HK1243346A1 (enExample)
HR (2) HRP20190693T1 (enExample)
HU (2) HUE044233T2 (enExample)
LT (1) LT2827863T (enExample)
PL (2) PL2827863T3 (enExample)
PT (2) PT3533447T (enExample)
RS (2) RS58744B1 (enExample)
SI (2) SI2827863T1 (enExample)
WO (1) WO2013142359A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054836T2 (hu) 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
JP6224064B2 (ja) 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
HRP20240056T1 (hr) * 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
CA3108321A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
JPWO2021014957A1 (enExample) * 2019-07-22 2021-01-28
WO2021161876A1 (ja) * 2020-02-10 2021-08-19 富士フイルム株式会社 ベンダムスチン液剤
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
NZ279443A (en) 1994-01-24 1998-04-27 Procter & Gamble Solubilizing difficultly soluble pharmaceutical agents using a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol
EP1004305B1 (en) 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
ES2300622T3 (es) 2002-07-30 2008-06-16 Wyeth Formulaciones parenterales que contienen un hidroxiester de rapamicina.
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
CA2585659A1 (en) 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2007026771A1 (ja) * 2005-08-31 2007-03-08 Ono Pharmaceutical Co., Ltd. 点滴用注射剤
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) * 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
EP2424506A1 (en) 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine
CN101584668A (zh) * 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
HUE054836T2 (hu) 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
US8604032B2 (en) * 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
AU2012347972B2 (en) 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
JP2015506989A (ja) 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
JP6224064B2 (ja) 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
HRP20240056T1 (hr) 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina

Also Published As

Publication number Publication date
DK3533447T3 (da) 2023-04-24
JP2022028813A (ja) 2022-02-16
PL3533447T3 (pl) 2023-07-17
JP2015510940A (ja) 2015-04-13
PL2827863T3 (pl) 2019-07-31
CN107157988A (zh) 2017-09-15
WO2013142359A1 (en) 2013-09-26
SI2827863T1 (sl) 2019-06-28
US9579384B2 (en) 2017-02-28
HRP20230276T1 (hr) 2023-04-28
HRP20190693T1 (hr) 2019-10-04
US20130253026A1 (en) 2013-09-26
US20150080444A1 (en) 2015-03-19
JP2024037915A (ja) 2024-03-19
CA2867343A1 (en) 2013-09-26
HUE044233T2 (hu) 2019-10-28
JP2018197248A (ja) 2018-12-13
EP2827863B1 (en) 2019-01-16
CN104271135B (zh) 2017-05-17
FI3533447T3 (fi) 2023-05-04
PT3533447T (pt) 2023-05-17
CA2867343C (en) 2020-08-11
LT2827863T (lt) 2019-06-10
EP3533447B1 (en) 2023-03-15
RS64137B1 (sr) 2023-05-31
SI3533447T1 (sl) 2023-06-30
US9000021B2 (en) 2015-04-07
HUE062230T2 (hu) 2023-10-28
JP6224064B2 (ja) 2017-11-01
US20150343061A1 (en) 2015-12-03
HK1243346A1 (zh) 2018-07-13
PT2827863T (pt) 2019-05-13
EP3533447A1 (en) 2019-09-04
EP2827863A4 (en) 2015-11-18
ES2718902T3 (es) 2019-07-05
CN104271135A (zh) 2015-01-07
ES2943668T3 (es) 2023-06-15
JP2018048153A (ja) 2018-03-29
JP2020143143A (ja) 2020-09-10
JP6738376B2 (ja) 2020-08-12
JP6381761B2 (ja) 2018-08-29
EP4218756A1 (en) 2023-08-02
DK2827863T3 (en) 2019-04-23
EP2827863A1 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
RS58744B1 (sr) Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje
JP7133070B2 (ja) ベンダムスチンの製剤
HK40097690A (en) Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
HK40013204A (en) Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
HK40013204B (en) Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration